CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On May25, 2018, the Company and its Chairman, President and Chief Executive Officer, Patrick J. McEnany, entered into an amendment to Mr.McEnany’s employment agreement with the Company extending the term of such agreement for an additional two year period. Mr.McEnany’s employment agreement with the Company now expires on November8, 2020. All of the other terms of Mr.McEnany’s employment agreement with the Company remain the same.
A copy of Amendment No.6 to Mr.McEnany’s employment agreement with the Company is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of Amendment No.6 that is set forth above is qualified in its entirety by reference to such amendment.
On May29, 2018, Patrick J. McEnany, the Chairman, President and Chief Executive Officer of the Company, was granted stock options to purchase 500,000 shares of the Company’s common stock at an exercise price of $3.54 per share, the closing price of the Company’s common stock on the date of grant. The options were granted to the Company’s 2018 Stock Incentive Plan and are seven-year options, vesting in equal tranches on the first, second, and third anniversaries of the grant date.
| Item 5.02 | Financial Statements and Exhibits. |
2
CATALYST PHARMACEUTICALS, INC. ExhibitEX-10.1 2 d467685dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT This SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT (Amendment) is entered into as of this 25th day of May,…To view the full exhibit click here
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.